sdAb Proteolytic Tolerance Improvement Service
Creative Biolabs is an indubitable leader in sdAb development and manufacture. With years of experience, our scientists employ the most advanced techniques to provide sdAb proteolytic tolerance improvement service for our customers all over the world.
While antibody therapeutics are traditionally administered through intravenous or subcutaneous routes, opportunities exist to deliver antibodies through other routes, such as oral delivery in addressing inflammatory bowel disease. For such potential therapeutic uses (prevention and/or treatment of digested bacterial pathogens), sdAbs which show high stability may be the choice of oral and nasal delivery to maintain function under extreme conditions (e.g., gastrointestinal environment). The extreme pH and protease-rich environment of the upper gastrointestinal tract is a significant obstacle facing orally administered antibody therapeutics. To use sdAbs as nasal or oral drugs, they should show chemical stability, particularly at the very low pH in the stomach and the presence of proteases such as pepsin and trypsin present in the stomach and intestinal tract, respectively, and the proteases produced by intestinal flora.
sdAb Proteolytic Tolerance Improvement Available at Creative Biolabs
The exceptional stability of sdAb opens the possibility for nonconventional therapeutic applications and alternative routes of administration. sdAbs usually display high chemical stability and proteolytic tolerance, but in some cases, sdAb stability needs to be increased further for their intended applications such as nasal or oral delivery.
Our scientists have multiple elegant solutions to predict the proteolytic susceptibility of sdAbs and to subsequently increase the proteolytic stability through genetic and protein engineering to accelerate our customers' sdAb development process.
At Creative Biolabs, several engineering and selection-based approaches are undertaken to improve the protease resistance of sdAbs, including but not limited to:
- Introduction of non-canonical disulfide bonds
- Rational removal of protease cleavage sites using site-directed mutagenesis
- Random mutagenesis (DNA shuffling) and stringent selection of proteolytically stable sdAbs
Meanwhile, we are also flexible enough to discuss the proposal with our customers or follow a published one to fulfill your specific demands. Through this tailored approach, we maximize the efficiency of sdAb proteolytic tolerance improvement, bringing cost-efficiencies and time-saving benefits.
Fig.1 sdAb proteolytic tolerance improvement. (Hagihara, 2012)
With advanced technologies and professional staff, Creative Biolabs is dedicated to offering first-class sdAb proteolytic tolerance improvement services to meet your goals of sdAb development in a time-saving manner. Our high-quality services will significantly contribute to the success of your projects. If you are interested in improving sdAb proteolytic tolerance, please do not hesitate to contact us for more details.
Reference
- Hagihara, Y.; Saerens, D. Improvement of single domain antibody stability by disulfide bond introduction. In Single Domain Antibodies. Humana Press, Totowa, NJ. 2012, pp. 399-416.
Case Study
We are offering highly customized CRO services to assist your Single Domain Antibody (sdAb) related projects. Please Contact Us for more details.
Services
